Log in

NYSE:ANIX - ITUS Stock Price, Forecast & News

+0.12 (+3.48 %)
(As of 02/19/2020 01:31 AM ET)
Today's Range
Now: $3.57
50-Day Range
MA: $3.43
52-Week Range
Now: $3.57
Volume74,900 shs
Average Volume60,941 shs
Market Capitalization$74.33 million
P/E RatioN/A
Dividend YieldN/A
Anixa Biosciences, Inc. engages in the development, acquisition and licensing emerging technology in the field of biotechnology. It focuses on platform called Cchek, a series of inexpensive non-invasive blood tests for the early detection of cancer, which is based on the body's immunological response to the presence of a malignancy. The company was founded on November 5, 1982 and is headquartered San Jose, CA.

Industry, Sector and Symbol

Industry Computer Peripherals
SectorElectronic Technology
Phone(408) 708-9808



Sales & Book Value

Annual SalesN/A



Market Cap$74.33 million
Next Earnings Date3/11/2020 (Estimated)
OptionableNot Optionable

Receive ANIX News and Ratings via Email

Sign-up to receive the latest news and ratings for ANIX and its competitors with MarketBeat's FREE daily newsletter.

ITUS (NYSE:ANIX) Frequently Asked Questions

What is ITUS's stock symbol?

ITUS trades on the New York Stock Exchange (NYSE) under the ticker symbol "ANIX."

When is ITUS's next earnings date?

ITUS is scheduled to release their next quarterly earnings announcement on Wednesday, March 11th 2020. View Earnings Estimates for ITUS.

What price target have analysts set for ANIX?

1 brokerages have issued 12-month target prices for ITUS's shares. Their forecasts range from $8.00 to $8.00. On average, they expect ITUS's stock price to reach $8.00 in the next year. This suggests a possible upside of 124.1% from the stock's current price. View Analyst Price Targets for ITUS.

What is the consensus analysts' recommendation for ITUS?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ITUS in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ITUS.

Has ITUS been receiving favorable news coverage?

Media headlines about ANIX stock have been trending positive on Wednesday, InfoTrie reports. InfoTrie rates the sentiment of media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. ITUS earned a media sentiment score of 2.8 on InfoTrie's scale. They also gave news articles about the company a news buzz of 4.0 out of 10, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next several days. View News Stories for ITUS.

Who are some of ITUS's key competitors?

What other stocks do shareholders of ITUS own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ITUS investors own include Enphase Energy (ENPH), Inseego (INSG), AbbVie (ABBV), IBM (IBM), Blink Charging (BLNK), Corbus Pharmaceuticals (CRBP), Etsy (ETSY), Gilead Sciences (GILD), Tesla (TSLA) and VBI Vaccines (VBIV).

Who are ITUS's key executives?

ITUS's management team includes the folowing people:
  • Amit Kumar, Executive Chairman, President & CEO
  • Michael J. Catelani, Chief Operating & Financial Officer
  • John A. Roop, Senior Vice President-Engineering
  • Anthony Campisi, Vice President-Engineering

How do I buy shares of ITUS?

Shares of ANIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is ITUS's stock price today?

One share of ANIX stock can currently be purchased for approximately $3.57.

How big of a company is ITUS?

ITUS has a market capitalization of $74.33 million. View Additional Information About ITUS.

How can I contact ITUS?

The company can be reached via phone at (408) 708-9808.

MarketBeat Community Rating for ITUS (NYSE ANIX)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  43 (Vote Outperform)
Underperform Votes:  51 (Vote Underperform)
Total Votes:  94
MarketBeat's community ratings are surveys of what our community members think about ITUS and other stocks. Vote "Outperform" if you believe ANIX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ANIX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/19/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel